Dark

Check out our API

CLVS
Clovis Oncology, Inc.
stock NASDAQ

Inactive

Dec 20, 2022

0.0812USD-5.581%(-0.0048)24,516,461

Pre-market

0.00USD-100.000%(-0.09)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 10, 2022

08:10AM EST Clovis Oncology : $35.5 Mln - $36.1 Mln In Estimated Rubraca Global Product Revenues For Q4 RTTNews

08:05AM EST Clovis Oncology Sees Q4 Rubraca Global Sales Of $35.5M-$36.1M, FY21 Rubraca Global Sales Of $148.3M-$148.9M Benzinga

08:00AM EST Clovis Oncology Announces Preliminary Financial Results for the Fourth Quarter and Full Year 2021 Business Wire

Dec 9, 2021

09:46PM EST Clovis Oncology Highlights FAP-2286 Preclinical Data Presented At The Targeted Radiopharmaceuticals Summit Benzinga

Nov 3, 2021

09:18AM EDT Clovis Oncology Q3 EPS $(0.56) Misses $(0.48) Estimate, Sales $37.92M Miss $39.09M Estimate Benzinga

09:10AM EDT Earnings Scheduled For November 3, 2021 Benzinga

08:17AM EDT Clovis Oncology Q3 Net Loss $67.4 Mln Vs Net Loss $78.7 Mln Last Year RTTNews

08:00AM EDT Clovis Oncology Announces Third Quarter 2021 Operating Results Business Wire

Oct 19, 2021

08:12AM EDT Clovis Oncology And ITM Announce Lutetium-177 Supply Agreement RTTNews

08:10AM EDT Clovis Oncology And ITM Announce Lutetium-177 Clinical Supply Agreement; ITM To Supply Lutetium-177 For Development Of Clovis Oncology's FAP-2286 Benzinga

08:00AM EDT Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement Business Wire

Oct 7, 2021

09:05AM EDT Clovis Oncology Says Pan-Cancer Analysis Suggests Fibroblast Activation Protein (FAP) Is Attractive Target For Peptide-Targeted Radionuclide Therapy With FAP-2286 Benzinga

Sep 24, 2021

07:58AM EDT Benzinga Pro's Top 5 Stocks To Watch For Friday, Sept. 24, 2021: TWTR, CRM, ZIVO, CLVS, MRM Benzinga

Sep 21, 2021

06:28AM EDT HC Wainwright & Co. Maintains Buy on Clovis Oncology, Lowers Price Target to $9 Benzinga

Sep 20, 2021

08:06AM EDT Clovis Oncology Retires Remaining 2021 Notes And Raises Additional Capital Through Its ATM Equity Offering Program Benzinga

Aug 20, 2021

07:45AM EDT The Daily Biotech Pulse: J&J Announces CEO Transition, FibroGen's Roxadustat Approved In Europe, GeoVax, Sorrento Announce COVID-19 Vaccine Data Benzinga

Aug 16, 2021

04:22PM EDT Clovis Oncology Reports Renewal Of At-The-Market Equity Offering for Up To $125M Benzinga

04:21PM EDT Clovis Oncology Announces Renewal of At-The-Market Equity Offering Program Business Wire

Aug 5, 2021

06:09AM EDT HC Wainwright & Co. Maintains Buy on Clovis Oncology, Lowers Price Target to $10 Benzinga

Aug 4, 2021

08:57AM EDT Clovis Oncology Earlier Reported Q2 Adj. EPS $(0.59) Misses $(0.56) Estimate, Sales $36.82M Miss $41.12M Estimate Benzinga

08:00AM EDT Clovis Oncology Announces Second Quarter 2021 Operating Results Business Wire

04:10AM EDT Earnings Scheduled For August 4, 2021 Benzinga

Jul 21, 2021

08:00AM EDT Clovis Oncology to Announce Second Quarter 2021 Financial Results and Host Webcast Conference Call on August 4 Business Wire

Jul 14, 2021

08:33AM EDT CLPS Incorporation To Take 15% Ownership Stake In UniDev Benzinga

Jun 28, 2021

07:08AM EDT Clovis Oncology Announces Its Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Has Been Published in The Journal of Nuclear Medicine Benzinga

07:00AM EDT Initial Clinical Experience of FAP-2286 in Independent Named Patient Use Published in The Journal of Nuclear Medicine Business Wire

Jun 27, 2021

10:22AM EDT Clovis Oncology Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) Posted to Clinical Trials Website on Friday; Study is Recruiting Benzinga

Jun 23, 2021

09:52AM EDT Clovis Oncology Shares Up 3% Ahead Of Previously-Adjourned Annual Shareholder Meeting To Vote On Proposal To Increase Number Of Shares Authorized For Issuance From 200M To 250M, Will Begin At 10:30 a.m. EDT Benzinga

07:09AM EDT Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open For Enrollment Benzinga

07:04AM EDT Clovis Oncology Says Phase 1/2 LuMIERE Study Of FAP-2286 Now Open For Enrollment RTTNews

07:00AM EDT Clovis Oncology Announces LuMIERE Clinical Trial Evaluating Novel Peptide-Targeted Radionuclide Therapy FAP-2286 Now Open for Enrollment Business Wire

Jun 10, 2021

04:30PM EDT Clovis Oncology Announces Partial Adjournment of Annual Meeting of Stockholders Business Wire

Jun 9, 2021

02:50PM EDT Mid-Afternoon Market Update: Dow Drops Over 50 Points; Comtech Telecommunications Shares Plunge Benzinga

08:49AM EDT Benzinga Pro's Top 5 Stocks To Watch For Wednesday, Jun. 9, 2021: EA, WISH, SCYX, COIN, CLVS Benzinga

May 18, 2021

07:44AM EDT The Daily Biotech Pulse: Spero Secures NIAID Funding, GlaxoSmithKline Releases COVID-19 Data, BioNTech Gets New CFO Benzinga

May 17, 2021

04:28PM EDT Clovis Oncology Announces $75M At-The-Market Equity Offering Program Benzinga

04:15PM EDT Clovis Oncology Announces At-The-Market Equity Offering Program Business Wire

May 5, 2021

12:19PM EDT HC Wainwright & Co. Maintains Buy on Clovis Oncology, Lowers Price Target to $12 Benzinga

10:04AM EDT Clovis Oncology Reports 11% Drop In Q1 Sales As COVID-19 Hit Rubraca Sales Benzinga

08:06AM EDT Clovis Oncology Q1 EPS $(0.64) Beats $(0.72) Estimate, Sales $38.10M Miss $44.55M Estimate Benzinga

07:43AM EDT The Daily Biotech Pulse: Athenex, NeoGenomics And Amryt In M&A Mix, European Nod For Roche's Cancer Immunotherapy, Earnings Deluge Continues Benzinga

04:16AM EDT Earnings Scheduled For May 5, 2021 Benzinga

Apr 30, 2021

09:39AM EDT Clovis Oncology Option Alert: Jan 21 $10 Calls Sweep (17) near the midpoint: 512 @ $1.25 vs 4330 OI; Earnings 5/5 Before Open Ref=$6.06 Benzinga

Apr 21, 2021

04:00PM EDT Clovis Oncology to Announce First Quarter 2021 Financial Results and Host Webcast Conference Call on May 5 Business Wire

Apr 12, 2021

09:48AM EDT Clovis Oncology Saturday Morning Highlighted Data On Rubraca Was Presented At American Association For Cancer Research Virtual Annual Meeting Benzinga

Mar 22, 2021

09:50AM EDT Return On Capital Employed Overview: Clovis Oncology Benzinga

Mar 19, 2021

02:59PM EDT Mid-Afternoon Market Update: Nasdaq Rises 100 Points; Idera Pharmaceuticals Shares Slide Benzinga

12:08PM EDT Mid-Day Market Update: BSQUARE Falls After Q4 Results; Clovis Oncology Shares Jump Benzinga

11:13AM EDT Return On Capital Employed Overview: Clovis Oncology Benzinga

10:11AM EDT Mid-Morning Market Update: Markets Open Lower; FedEx Beats Q3 Estimates Benzinga

08:00AM EDT Clovis Oncology's Rubraca(r) (rucaparib) Significantly Improves Progression-Free Survival versus Chemotherapy in Patients with Later-line Ovarian Cancer Associated with a BRCA Mutation Business Wire

Feb 23, 2021

09:24AM EST Clovis Oncology: Q4 Earnings Insights Benzinga

08:04AM EST Clovis Oncology Reports Q4 Rubraca Global Net Sales $43.3M, FY20 Rubraca Global Net Sales $164.5M Benzinga

07:25AM EST The Daily Biotech Pulse: Aridis To Study Antibody Cocktail For Coronavirus Variants, Revance & Protalix Data Readouts Benzinga

04:09AM EST Earnings Scheduled For February 23, 2021 Benzinga

Feb 22, 2021

10:14AM EST Earnings Preview for Clovis Oncology Benzinga

Feb 6, 2021

12:42PM EST The Week Ahead In Biotech (Feb. 7-13): Regeneron FDA Decision, Earnings, IPOs and Conference Presentations In The Spotlight Benzinga

Jan 11, 2021

08:16AM EST Clovis Oncology Sees Prelim. Q4 Rubraca Sales $43.0M-$43.5M, FY20 Rubraca Sales $164.2M-$164.7M Benzinga

Dec 29, 2020

08:03AM EST Clovis Oncology Reports Submission Of Investigational New Drug Applications For Novel Peptide-Targeted Radionuclide FAP-2286 For Therapeutic, Imaging Trial Benzinga

Dec 21, 2020

10:05AM EST Looking Into Clovis Oncology's Return On Capital Employed Benzinga

08:04AM EST Clovis Oncology's Rubraca Meets Primary Endpoint Of Significantly Improving Progression-Free Survival Vs. Chemotherapy In ARIEL4 Randomized Phase 3 Treatment Study In Later-Line Ovarian Cancer Patients With BRCA Mutation Benzinga

Dec 4, 2020

06:15AM EST Clovis Oncology S-3 Shows Registration For 10.14M Share Common Stock Offering Issuable Upon Conversion Of $57.5M Convertible Senior Notes Benzinga

Nov 24, 2020

06:06PM EST Clovis Oncology Announces Exercise by Existing Holder of Option to Purchase an Additional $7.5 Million Aggregate Principal Amount of the Company's 4.50% Convertible Senior Notes Due 2024 Business Wire

Nov 6, 2020

10:37AM EST SVB Leerink Maintains Underperform on Clovis Oncology, Lowers Price Target to $3 Benzinga

06:28AM EST HC Wainwright & Co. Maintains Buy on Clovis Oncology, Lowers Price Target to $15 Benzinga

Nov 5, 2020

12:15PM EST Mid-Day Market Update: Silver Surges 5%; Hanesbrands Shares Plunge Benzinga

11:42AM EST Yahoo Finance Trending Stocks For Thursday, Nov. 5, 2020: QCOM, XPEV, UPWK, ACB, BIIB, GM, KXIN, FROG, HOFV, BLUE, TEVA, LIN, TLRY, HBI, PLTR, OPTI, CLVS, ZNGA, APHA, BABA, ALTM, GOLD, MFA, IIVI, PING, ACB, QRVO, ESALY Benzinga

10:24AM EST Mid-Morning Market Update: Markets Open Higher; General Motors Profit Tops Estimates Benzinga

08:10AM EST Clovis Oncology Q3 EPS $(0.89) Beats $(0.99) Estimate, Sales $38.77M Miss $42.64M Estimate Benzinga

07:54AM EST The Daily Biotech Pulse: Bluebird Bio Plunges On Regulatory Filing Delay, Synlogic Soars On Study Initiation, European Label Expansion For Vertex, Merck Goes Shopping Benzinga

04:34AM EST Earnings Scheduled For November 5, 2020 Benzinga

Nov 2, 2020

08:59AM EST Morgan Stanley Maintains Equal-Weight on Rocket Companies, Lowers Price Target to $23 Benzinga

Nov 1, 2020

09:40AM EST The Week Ahead In Biotech (Nov. 1-7): Adcom Test For Biogen's Aducanumab, Alzheimer's Conference, SMID-cap Earnings Benzinga

Oct 13, 2020

10:59AM EDT Clovis Oncology Option Alert: Jan 15 $10 Calls Sweep (2) near the Ask: 1432 @ $0.801 vs 8436 OI; Earnings 11/5 Before Open [est] Ref=$5.72 Benzinga

Oct 7, 2020

02:20PM EDT Clovis Oncology Option Alert: Jan 15 $7 Calls Sweep (7) near the Ask: 197 @ $1.35 vs 1841 OI; Earnings 11/5 Before Open [est] Ref=$5.75 Benzinga

Sep 30, 2020

02:48PM EDT Clovis Oncology Option Alert: Jan 15 $8 Calls Sweep (7) near the Ask: 200 @ $1.343 vs 14771 OI; Earnings 11/5 Before Open [est] Ref=$5.81 Benzinga

Sep 21, 2020

03:02PM EDT Clovis Oncology Option Alert: Oct 16 $6 Puts Sweep (4) near the Bid: 5050 @ $0.38 vs 2109 OI; Earnings 11/5 Before Open [est] Ref=$7.215 Benzinga

Sep 17, 2020

03:05AM EDT New Data Presented at ESMO Virtual Congress 2020 Highlight Breadth and Potential of Clovis Oncology Products and Pipeline Business Wire

Sep 15, 2020

08:24AM EDT Benzinga Pro's Top 5 Stocks To Watch For Tuesday, Sept. 15, 2020: SNOW, NVAX, NKLA, CLVS, WKHS Benzinga

Sep 9, 2020

08:05AM EDT Clovis Oncology to Highlight Data for its Three Portfolio Compounds at the ESMO Virtual Congress 2020 Business Wire

Sep 8, 2020

04:19PM EDT Clovis Oncology to Present at the H.C. Wainwright 22nd Annual Global Investment Conference Business Wire

Sep 1, 2020

03:18PM EDT Plasma Stocks Quiet; Reuters Reports NIH Advisors Say Data Fail To Back Trump-Backed Plasma Therapy Benzinga

Aug 27, 2020

09:58AM EDT ROCE Insights For Clovis Oncology Benzinga

05:52AM EDT Clovis Oncology Announced FDA Approved FoundationOne Liquid CDx to Serve as Rubraca Companion Diagnostic to Identify Eligible Patients with BRCA1/2-Mutant, Metastatic Castration-Resistant Prostate Cancer Benzinga

Aug 18, 2020

10:36AM EDT Return On Capital Employed Overview: Clovis Oncology Benzinga

Aug 17, 2020

03:13PM EDT Why Clovis Oncology's Stock Is Trading Higher Today Benzinga

08:15AM EDT Clovis Oncology Shares Move Higher; Journal Of Clinical Oncology Publishes Additional Data From Co.'s TRITON2 Clinical Trial Evaluating Rubraca For Treatment Of mCRPC In Patients With BRCA1/2 Gene Mutations Benzinga

08:05AM EDT Journal of Clinical Oncology Publishes Additional Data from Clovis Oncology's TRITON2 Clinical Trial Evaluating Rubraca(r) (rucaparib) for the Treatment of mCRPC in Patients with BRCA1/2 Gene Mutations Business Wire

Aug 6, 2020

04:27PM EDT Clovis Oncology Q2 EPS $(1.15) Misses $(1.04) Estimate, Sales $39.90M Miss $44.65M Estimate Benzinga

Aug 5, 2020

08:12AM EDT Clovis Oncology Announces First Patient Enrolled In Phase 2 Portion Of The LIO-1 Trial Evaluating The Combination Of Lucitanib And Opdivo In Gynecologic Cancers Benzinga

Share